Key result
Prior ACE inhibitor or ARB use shows no significant mortality benefit over other antihypertensives in COVID-19.
Why the study?
Differences in disease severity and outcomes among hypertensive COVID-19 patients using ACE inhibitors, ARBs, or other antihypertensive drugs were unclear.
Does prior use of ACE inhibitors or ARBs improve clinical outcomes in hypertensive patients hospitalized with COVID-19 compared to other antihypertensive drugs?
Cross-Sectional (n=153)
No
Does prior use of ACE inhibitors or ARBs improve clinical outcomes in hypertensive patients hospitalized with COVID-19 compared to other antihypertensive drugs?
In hypertensive patients hospitalized with COVID-19, prior use of ACE inhibitors or ARBs was not associated with significantly different rates of mortality, ICU admission, or intubation compared to other antihypertensive drugs.
Answers are grounded in this paper and cite their sources.
No significant mortality difference with prior ACEi/ARB use; leaves open their prognostic role in hypertensive COVID-19.
Background: To investigate differences in disease severity and outcomes among COVID-19 patients with a history of hypertension using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antihypertensive drugs. Materials and Methods: Based on drug exposure, 153 hypertensive patients with COVID-19 were divided into three groups: angiotensin-converting enzyme inhibitor group, angiotensin receptor blocker group, and other antihypertensive drugs group. The outcomes, laboratory and clinical results, were compared. Results: The frequency of ICU admission among patients in the angiotensin receptor blocker, angiotensin-converting enzyme inhibitor, and other antihypertensive drug groups was 25.5%, 27.8%, and 23.2%, respectively. The intubation frequency was 23.6%, 27.8%, and 30.4%, respectively. The longest hospital stay was observed in the angiotensin-converting enzyme inhibitor group, but the difference was not significant (P>0.05). The mortality rates were highest in the other antihypertensive drug groups. Conclusion: Patients with COVID-19 who consume angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have lower mortality rates compared to patients consuming other antihypertensive drugs.
No takes yet. Share an insight, caveat, or question.
Shojaei et al. (2026) conducted a cross-sectional in COVID-19 with hypertension (n=153). ACE inhibitors and ARBs vs. Other antihypertensive drugs was evaluated on Mortality (p=>0.05). Prior use of ACE inhibitors or ARBs in hypertensive patients with COVID-19 was associated with lower mortality rates compared to other antihypertensive drugs (27.8% and 23.6% vs 30.4%), though the difference was not statistically significant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: